Alterity director discloses option and share holdings
Alterity Therapeutics director Peter Ashley Marks filed an initial Form 3 reporting his beneficial holdings in the company.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Alterity Therapeutics director Peter Ashley Marks filed an initial Form 3 reporting his beneficial holdings in the company. He indirectly holds 1,818,182 Ordinary shares through Shanti Capital Pty Ltd <Peter Marks Super Fund A/C>. He also holds listed options over 606,061 Ordinary shares with a conversion price of $0.028 per share expiring on 26 Feb 2027, and unlisted options over 30,000,000 Ordinary shares with a conversion price of $0.010 per share expiring on 30 Dec 2027.
Insider Trade Summary
Holdings reported, no transactions
Holdings
Insider
Marks Peter Ashley
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Listed option exp 26 Feb 2027 | -- | -- | -- |
| Holding | Unlisted option exp 30 Dec 2027 | -- | -- | -- |
| Holding | Ordinary shares | -- | -- | -- |
Holdings:
Listed option exp 26 Feb 2027 — 606,061 contracts (Indirect, Shanti Capital Pty Ltd <Peter Marks Super Fund A/C>);
Unlisted option exp 30 Dec 2027 — 30,000,000 contracts (Direct);
Ordinary shares — 1,818,182 shares (Indirect, Shanti Capital Pty Ltd <Peter Marks Super Fund A/C>)
Key Figures
Indirect Ordinary shares: 1,818,182 shares
Listed option underlying shares: 606,061 shares
Listed option exercise price: $0.028/share
+2 more
5 metrics
Indirect Ordinary shares
1,818,182 shares
Indirect holdings via Shanti Capital Pty Ltd <Peter Marks Super Fund A/C>
Listed option underlying shares
606,061 shares
Listed option expiring 26 Feb 2027 over Ordinary shares
Listed option exercise price
$0.028/share
Conversion or exercise price for listed option expiring 26 Feb 2027
Unlisted option underlying shares
30,000,000 shares
Unlisted option expiring 30 Dec 2027 over Ordinary shares
Unlisted option exercise price
$0.010/share
Conversion or exercise price for unlisted option expiring 30 Dec 2027
Key Terms
Form 3, beneficial holdings, Ordinary shares, listed options, +2 more
6 terms
Form 3 regulatory
"filed an initial Form 3 reporting his beneficial holdings in the company"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
beneficial holdings financial
"filed an initial Form 3 reporting his beneficial holdings in the company"
listed options financial
"He also holds listed options over 606,061 Ordinary shares with a conversion price"
Listed options are standardized contracts traded on an exchange that give the buyer the right, but not the obligation, to buy or sell a specific stock or other security at a fixed price before a set date. Think of them like exchange-backed coupons that let investors lock in a price, offering a tool for protecting a portfolio, generating income, or making a concentrated bet—with the benefits of transparent pricing and easier trading compared with private contracts.
unlisted options financial
"and unlisted options over 30,000,000 Ordinary shares with a conversion price"
A contract that gives a specific person the right to buy or sell shares but is not traded on a public exchange; these are issued privately or over the counter, including many employee stock options or bespoke dealer agreements. They matter to investors because they are harder to value and trade, carry higher counterparty and transparency risk, and can create unexpected share dilution or contingent obligations for a company — like a custom coupon that only a few people can use instead of a store-wide voucher.
indirect ownership financial
"He indirectly holds 1,818,182 Ordinary shares through Shanti Capital Pty Ltd"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Alterity Therapeutics (ATHE) Form 3 filing show for Peter Ashley Marks?
The Form 3 shows director Peter Ashley Marks’ initial beneficial ownership in Alterity Therapeutics, including 1,818,182 Ordinary shares held indirectly and significant option positions over additional Ordinary shares with defined exercise prices and expiration dates.
What listed options in ATHE does Peter Ashley Marks report on Form 3?
He reports listed options expiring 26 Feb 2027 over 606,061 Ordinary shares of Alterity Therapeutics, with a conversion or exercise price of $0.028 per share. These options are held indirectly through Shanti Capital Pty Ltd <Peter Marks Super Fund A/C>.
What unlisted options in Alterity Therapeutics (ATHE) does Peter Ashley Marks hold?
He holds unlisted options expiring 30 Dec 2027 over 30,000,000 Ordinary shares of Alterity Therapeutics at a conversion or exercise price of $0.010 per share. These options are reported as directly held in the Form 3 filing.
Does the ATHE Form 3 filing show any recent buying or selling by Peter Ashley Marks?
The Form 3 is an initial beneficial ownership report and lists holdings rather than explicit purchases or sales. Transaction codes are shown as unknown, and the filing focuses on existing share and option positions instead of new trading activity.
AI-generated analysis. How Rhea-AI works. Not financial advice.
